Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Wednesday. $118.28 million flowed into the stock on the tick-up and $256.23 million flowed out of the stock on the tick-down, for a money net flow of $137.95 million out of the stock. Of all companies tracked, Johnson & Johnson had the 2nd highest net out-flow for the day. Johnson & Johnson traded up $0.09 for the day and closed at $122.63

Several equities analysts have recently issued reports on JNJ shares. Citigroup cut their price objective on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a report on Tuesday, February 27th. Jefferies Financial Group set a $165.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, February 26th. Vetr downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price target on the stock. in a report on Monday, March 26th. TheStreet downgraded shares of Johnson & Johnson from an “a” rating to a “c+” rating in a report on Monday, March 26th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 price target on the stock in a report on Wednesday, March 28th. Six research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $142.23.

The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $329.08 billion, a P/E ratio of 16.80, a P/E/G ratio of 1.88 and a beta of 0.73.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The business had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. During the same quarter in the prior year, the firm posted $1.83 EPS. The business’s quarterly revenue was up 12.6% compared to the same quarter last year. analysts forecast that Johnson & Johnson will post 8.13 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th were given a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.94%. The ex-dividend date of this dividend was Friday, May 25th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

Institutional investors have recently added to or reduced their stakes in the business. Goodman Financial Corp purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $104,000. Financial Gravity Wealth Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $105,000. Stelac Advisory Services LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $108,000. Princeton Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $141,000. Finally, Price Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $148,000. Institutional investors and hedge funds own 66.03% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.